Volume 17, Number 8—August 2011
Saffold Virus Infection in Children, Malaysia, 2009
Highlight and copy the desired format.
|EID||Chua KB, Voon K, Yu M, Ali WN, Kasri AR, Wang L, et al. Saffold Virus Infection in Children, Malaysia, 2009. Emerg Infect Dis. 2011;17(8):1562-1564. https://dx.doi.org/10.3201/eid1708.101380|
|AMA||Chua KB, Voon K, Yu M, et al. Saffold Virus Infection in Children, Malaysia, 2009. Emerging Infectious Diseases. 2011;17(8):1562-1564. doi:10.3201/eid1708.101380.|
|APA||Chua, K. B., Voon, K., Yu, M., Ali, W. N., Kasri, A. R., & Wang, L. (2011). Saffold Virus Infection in Children, Malaysia, 2009. Emerging Infectious Diseases, 17(8), 1562-1564. https://dx.doi.org/10.3201/eid1708.101380.|
To the Editor: Since 2007, a new cardiovirus, named Saffold virus (SAFV), has been isolated from human specimens in the United States, Canada, the Netherlands, and People’s Republic of China (1–4). Concurrent investigations also showed that SAFV could be detected in feces and respiratory secretions of children in other countries, and genetic analysis showed the circulation of different genetic lineages of SAFVs in various parts of the world. This new virus belongs to the genus Cardiovirus, in the family Picornaviridae (5). Here we report isolation of a new SAFV in Malaysia, designated SAFV-Penang to reflect the locality of isolation in Malaysia.
A 5-year-old girl was brought to a government outpatient clinic on November 18, 2009, with reported fever and sore throat for 3 days. The fever was described as of high grade with occasional episodes of rigor, accompanied by profuse sweating and myalgia, lethargy, and loss of appetite. The child had nasal blockage, mild runny nose, and dry cough. She vomited twice on day 3 of illness and had abdominal pain but no diarrhea. There was no history of similar illness affecting other family members, who lived in a semirural area within the state of Penang, Malaysia. Acute pharyngitis/acute influenza-like illness was provisionally diagnosed, and a throat swab specimen was collected in virus transport medium for virus isolation by using established procedures (6).
The throat swab sample was treated with antimicrobial drugs for 1 h before the cells were added to MDCK, Vero, and Hep-2 cells. On the fifth day postinoculation (dpi), a lytic form of cytopathic effect (CPE), similar to the type of CPE from enterovirus infection, was noted in Hep-2 but not in Vero or MDCK cells. The progress of CPE was slow, and full CPE was achieved on 9 dpi. On 8 dpi, a 0.5-mL aliquot containing infected Hep-2 cell suspension was removed and processed for indirect immunofluorescence assay by using a panel of commercial typing monoclonal antibodies for human enteroviruses. The infected Hep-2 cells reacted strongly with broad reactive pan-enterovirus monoclonal antibodies (catalog no. 3360, Chemicon Inc., Temecula, CA, USA) but failed to react with any type-specific monoclonal antibodies (data not shown).
After 3 passages in Hep-2 cells, culture supernatant was subsequently passed into Vero cells. After an additional 3 passages, the virus was fully adapted to grow in Vero cells and was able to induce visible CPE 1 dpi and full CPE by 4 dpi.
Partial genome sequence of the virus was initially obtained by using a random priming and amplification method as described (7). Full-length sequence was then determined by using primers designed according to the partial genome sequences of SAFV-Penang and genome sequences of other SAFV strains available in GenBank (primer sequences are available on request). The viral genome of SAFV-Penang is 8,073 nt (full sequence deposited in GenBank under accession no. HQ162476). As for other SAFVs, a single long open reading frame of 2,295 aa was detected. Phylogenetic analysis based on the complete amino acid sequences of the polyproteins of different SAFVs indicated that SAFV-Penang is a type 3 SAFV (8). It is most closely related to the SAFV-3 isolated in the Netherlands in 2007.
To determine the prevalence of SAFV infection among children in Malaysia, we conducted a seroprevalence study by using 400 serum samples collected during 2009 from children 10–12 years of age under the national hepatitis B postvaccination serosurvey. The serum panel comprised 80 samples containing equal numbers of boys and girls from each of the 5 states: Penang (northwestern), Selangor (central-western), and Kelantan (northeastern) of peninsular Malaysia, and Sabah and Sarawak of eastern Malaysia in Borneo Island. Screening for SAFV-specific antibodies was conducted by using an indirect immunofluorescence antibody test on SAFV-infected Vero cells as described (9). The results (Table) indicated that >70% of schoolchildren surveyed had been exposed to the virus. The seropositive rate ranged from 67.5% (Penang) to 75.0% (Kelantan and Sabah), with no significant difference among different parts of the country (χ2 = 1.60, df = 4, p = 0.8091). The seropositive rate did not differ significantly by sex (χ2 = 0.32, p = 0.5734).
In summary, a new SAFV was discovered in Malaysia by direct virus isolation during an investigation of a febrile patient. Subsequent serologic study indicated that a high percentage of children 10–12 years of age had been exposed to this virus. Further study is required to determine the public health implications of SAFV infection in Southeast Asia, especially in cases in which co-infection with other pathogens might potentially lead to different clinical outcomes.
This work was supported in part by research grants from the International Medical University of Malaysia and the Commonwealth Scientific and Industrial Research Organisation Livestock Industries, Australian Animal Health Laboratory.
- Jones MS, Lukashov VV, Ganac RD, Schnurr DP. Discovery of a novel human picornavirus in a stool sample from a pediatric patient presenting with fever of unknown origin. J Clin Microbiol. 2007;45:2144–50.
- Abed Y, Boivin G. New Saffold cardioviruses in 3 children, Canada. Emerg Infect Dis. 2008;14:834–6.
- Zoll J, Erkens Hulshof S, Lanke K, Verduyn Lunel F, Melchers WJ, Schoondermark-van de Ven E, Saffold virus, a human Theiler's-like cardiovirus, is ubiquitous and causes infection early in life. PLoS Pathog. 2009;5:e1000416.
- Chiu CY, Greninger AL, Chen EC, Haggerty TD, Parsonnet J, Delwart E, Cultivation and serological characterization of a human Theiler's-like cardiovirus associated with diarrheal disease. J Virol. 2010;84:4407–14.
- Racanielle VR. Picornaviridae: the viruses and their replication. In: Knipe DM, Griffin DE, Lamb RA, Straus SE, Howley PM, Martin MA, et al., editors. Fields virology. Philadelphia (PA): Lippincott Williams & Wilkins; 2007. p. 795–842.
- Chua KB, Crameri G, Hyatt A, Yu M, Tompang MR, Rosli J, A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humans. Proc Natl Acad Sci U S A. 2007;104:11424–9.
- Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A. 2005;102:12891–6.
- Liang Z, Kumar AS, Jones MS, Knowles NJ, Lipton HL. Phylogenetic analysis of the species Theilovirus: emerging murine and human pathogens. J Virol. 2008;82:11545–54.
- Chua KB, Khairullah NS, Hooi PS. Seroepidemiology of human herpesvirus 6 in a population seen in the University Hospital, Kuala Lumpur, Malaysia. Southeast Asian J Trop Med Public Health. 1996;27:91–5.
- Table. Prevalence of SAFV-specific IgG in serum from children 10–12 years of age, by sex, Malaysia, 2009
Please use the form below to submit correspondence to the authors or contact them at the following address:
Lin-Fa Wang, CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria, Australia
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: August 15, 2011
- Page last updated: August 15, 2011
- Page last reviewed: August 15, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)